Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Merimepodib (VX-497) 是一种新型非竞争性肌苷一磷酸脱氢酶抑制剂,具有广谱抗病毒活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 393 | 现货 | ||
5 mg | ¥ 938 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,780 | 现货 | ||
50 mg | ¥ 3,970 | 现货 | ||
100 mg | ¥ 5,790 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 933 | 现货 |
产品描述 | Merimepodib (VX-497) is a novel noncompetitive inhibitor of Inosine monophosphate dehydrogenase(IMPDH). |
体外活性 | VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. VX-497 (MW 452.5) is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2]. |
体内活性 | Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is shown to be as effective as twice-daily dosing in this model of immune activation[1]. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals[3]. |
细胞实验 | The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM?l-glutamine. EMCV is infected at 500 PFU/107?L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof. |
别名 | 美泊地布, VX-497, VI-21497 |
分子量 | 452.46 |
分子式 | C23H24N4O6 |
CAS No. | 198821-22-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL (68.51 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2101 mL | 11.0507 mL | 22.1014 mL | 55.2535 mL |
5 mM | 0.442 mL | 2.2101 mL | 4.4203 mL | 11.0507 mL | |
10 mM | 0.221 mL | 1.1051 mL | 2.2101 mL | 5.5254 mL | |
20 mM | 0.1105 mL | 0.5525 mL | 1.1051 mL | 2.7627 mL | |
50 mM | 0.0442 mL | 0.221 mL | 0.442 mL | 1.1051 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Merimepodib 198821-22-6 Immunology/Inflammation Metabolism Microbiology/Virology Proteases/Proteasome Dehydrogenase HCV Protease Antiviral HBV 美泊地布 HCV Inhibitor Hepatitis C virus Hepatitis B virus VX497 VX 497 inhibit MMPD VI 21497 VX-497 VI-21497 VI21497 inhibitor